Gracell inks $85 mln Series B

China-based Gracell, a cellular gene therapy company, has secured $85 million in Series B funding. Temasek led the round with participation from Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji.

Source: Press Release